These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 24182320)
21. Drug discovery strategies for acute radiation syndrome. Singh VK; Seed TM; Olabisi AO Expert Opin Drug Discov; 2019 Jul; 14(7):701-715. PubMed ID: 31008662 [No Abstract] [Full Text] [Related]
22. Working with the U.S. Food and Drug Administration to obtain approval of products under the Animal Rule. Park GD; Mitchel JT Ann N Y Acad Sci; 2016 Jun; 1374(1):10-6. PubMed ID: 27336401 [TBL] [Abstract][Full Text] [Related]
23. Tissue-protective effects of fullerenol C60(OH)24 and amifostine in irradiated rats. Trajković S; Dobrić S; Jaćević V; Dragojević-Simić V; Milovanović Z; Dordević A Colloids Surf B Biointerfaces; 2007 Jul; 58(1):39-43. PubMed ID: 17317115 [TBL] [Abstract][Full Text] [Related]
24. Radioprotection and Radiomitigation: From the Bench to Clinical Practice. Obrador E; Salvador R; Villaescusa JI; Soriano JM; Estrela JM; Montoro A Biomedicines; 2020 Oct; 8(11):. PubMed ID: 33142986 [TBL] [Abstract][Full Text] [Related]
25. Biosimilars: the need, the challenge, the future: the FDA perspective. Epstein MS; Ehrenpreis ED; Kulkarni PM; Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160 [TBL] [Abstract][Full Text] [Related]
26. Early results of the screening program for radioprotectors. Brown DQ; Pittock JW; Rubinstein JS Int J Radiat Oncol Biol Phys; 1982; 8(3-4):565-70. PubMed ID: 7050040 [TBL] [Abstract][Full Text] [Related]
27. A Method for Approximating Future Entry of Generic Drugs. Beall RF; Darrow JJ; Kesselheim AS Value Health; 2018 Dec; 21(12):1382-1389. PubMed ID: 30502781 [TBL] [Abstract][Full Text] [Related]
28. Radiation protectants: current status and future prospects. Seed TM Health Phys; 2005 Nov; 89(5):531-45. PubMed ID: 16217197 [TBL] [Abstract][Full Text] [Related]
29. Development of radiation countermeasure agents for acute radiation syndromes. Guan B; Li D; Meng A Animal Model Exp Med; 2023 Aug; 6(4):329-336. PubMed ID: 37642199 [TBL] [Abstract][Full Text] [Related]
30. A Metabolomic Serum Signature from Nonhuman Primates Treated with a Radiation Countermeasure, Gamma-tocotrienol, and Exposed to Ionizing Radiation. Pannkuk EL; Laiakis EC; Fornace AJ; Fatanmi OO; Singh VK Health Phys; 2018 Jul; 115(1):3-11. PubMed ID: 29787425 [TBL] [Abstract][Full Text] [Related]
31. Determinants of Market Exclusivity for Prescription Drugs in the United States. Kesselheim AS; Sinha MS; Avorn J JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528 [TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical trademarks: navigating through the FDA's pilot program. Ferrer E Drug News Perspect; 2010 Jun; 23(5):333-6. PubMed ID: 20603657 [TBL] [Abstract][Full Text] [Related]
33. Origins of medical innovation: the case of coronary artery stents. Xu S; Avorn J; Kesselheim AS Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):743-9. PubMed ID: 23093563 [TBL] [Abstract][Full Text] [Related]
35. Molecular farming, patents and access to medicines. Drake PM; Thangaraj H Expert Rev Vaccines; 2010 Aug; 9(8):811-9. PubMed ID: 20673006 [TBL] [Abstract][Full Text] [Related]
36. Pediatric exclusivity: evolving legislation and novel complexities within pediatric therapeutic development. Rivera DR; Hartzema AG Ann Pharmacother; 2014 Mar; 48(3):369-79. PubMed ID: 24311725 [TBL] [Abstract][Full Text] [Related]
37. Bacq and Alexander Award lecture--chemical radioprotection: past, present, and future prospects. Maisin JR Int J Radiat Biol; 1998 Apr; 73(4):443-50. PubMed ID: 9587083 [TBL] [Abstract][Full Text] [Related]
38. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study. Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641 [TBL] [Abstract][Full Text] [Related]
39. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh. Basile EM; Tolomeo D; Gluck E Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744 [TBL] [Abstract][Full Text] [Related]
40. The patents-based pharmaceutical development process: rationale, problems, and potential reforms. Barton JH; Emanuel EJ JAMA; 2005 Oct; 294(16):2075-82. PubMed ID: 16249422 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]